These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 83419)

  • 1. [Urodynamic study of lower urinary tract. VI. Clinical application of alpha adrenergic blocker for the treatment of benign prostatic hypertrophy and bladder neck contracture (author's transl)].
    Kondo A; Narita H; Otani T; Kobayashi M; Takita T
    Nihon Hinyokika Gakkai Zasshi; 1978 Oct; 69(10):1232-40. PubMed ID: 83419
    [No Abstract]   [Full Text] [Related]  

  • 2. [Alpha adrenergic blocking agents in disorders of the bladder sphincter].
    Perrigot M; Vannier A; Bor Y
    Rev Prat; 1986 Jan; 36(5):223-8. PubMed ID: 2421393
    [No Abstract]   [Full Text] [Related]  

  • 3. [Generally effective for unstable bladder? Tamsulosin: application not limited to benign prostatic hyperplasia].
    Urologe A; 2003 Feb; 42(2):301-2. PubMed ID: 12739514
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical efficacy of oxendolene (antiandrogen) and bunazosin hydrochloride (alpha-adrenergic blocker) in the treatment of prostatism--comparative study of oxendolone, bunazocin hydrochloride and their combination].
    Kumamoto Y; Tsukamoto T; Takagi Y; Furuya S; Yokoyama E; Takatsuka K; Tamiya T; Miyamoto S; Aoyama T; Honma A
    Hinyokika Kiyo; 1987 Nov; 33(11):1921-41. PubMed ID: 2451412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Alfuzosin in benign prostatic hyperplasia. A new principle is evaluated. Report of a study].
    Fortschr Med Suppl; 1995; 166():1-12. PubMed ID: 7537599
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
    Martorana G; Giberti C; Di Silverio F; von Heland M; Rigatti P; Colombo R; Casadei G; Pacifico P
    Eur Urol; 1997; 32(1):47-53. PubMed ID: 9266231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
    Kaplan SA
    J Urol; 2005 Sep; 174(3):1011. PubMed ID: 16094031
    [No Abstract]   [Full Text] [Related]  

  • 8. Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis.
    Witjes WP; Rosier PF; Caris CT; Debruyne FM; de la Rosette JJ
    Urology; 1997 Feb; 49(2):197-205; discussion 205-6. PubMed ID: 9037281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical management of lower urinary tract symptoms with combined medical therapy.
    Roehrborn CG
    BJU Int; 2008 Nov; 102 Suppl 2():13-7. PubMed ID: 19032605
    [No Abstract]   [Full Text] [Related]  

  • 10. [Two drugs have a better outcome. Finasteride plus alpha blocker improves urine flow].
    MMW Fortschr Med; 2003 Nov; 145(47):62. PubMed ID: 14725041
    [No Abstract]   [Full Text] [Related]  

  • 11. BPH alpha blocker therapy.
    Vela-Navarrete R
    J Urol (Paris); 1995; 101(1):26-8. PubMed ID: 7545722
    [No Abstract]   [Full Text] [Related]  

  • 12. Phenoxybenzamine reduces bladder outlet obstruction in benign prostatic hyperplasia. A urodynamic investigation.
    Gerstenberg T; Blaabjerg J; Nielsen ML; Clausen S
    Invest Urol; 1980 Jul; 18(1):29-31. PubMed ID: 6157651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
    Gerber GS; Kim JH; Contreras BA; Steinberg GD; Rukstalis DB
    Urology; 1996 Jun; 47(6):840-4. PubMed ID: 8677574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Established and upcoming new options in medical therapy for benign prostatic hyperplasia].
    Schlenker B; Beer AM; Gratzke C; Tilki D; Seitz M; Stief CG; Reich O
    MMW Fortschr Med; 2009 Oct; 151(41):33-6. PubMed ID: 19891182
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiovascular effects of alpha-blockers for the treatment of symptomatic BPH.
    de Mey C
    Eur Urol; 1998; 34 Suppl 2():18-28; discusion 47. PubMed ID: 9732829
    [No Abstract]   [Full Text] [Related]  

  • 16. The resolution of detrusor over activity after medical and surgical treatment in patients with bladder outlet obstruction.
    Sriplakich S; Promwatcharanon K
    J Med Assoc Thai; 2007 Nov; 90(11):2326-31. PubMed ID: 18181315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Phenoxybenzamine in prostatic pathology. 300 cases (author's transl)].
    Lardennois B; El Khansa A; Amory JP; Coulon JM; Lemaire P
    J Urol (Paris); 1981; 87(4):243-8. PubMed ID: 6167646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased bladder apoptosis with alpha-1 adrenoceptor antagonists in benign prostatic hyperplasia.
    Erdoğru T; Gülkesen KH; Kukul E; Yalçinkaya M; Karpuzoğlu G; Baykara M
    Scand J Urol Nephrol; 2002; 36(3):188-93. PubMed ID: 12201933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists.
    Andersson KE
    World J Urol; 2002 Apr; 19(6):390-6. PubMed ID: 12022707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia: evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractility.
    Song K; Choo MS; Lee KS; Han JY; Lee YS; Kim JC; Cho JS
    Urology; 2011 May; 77(5):1177-82. PubMed ID: 21256567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.